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Abstract
Immunoglobulin molecule is the key component of B cell receptor (BCR), which 
­governs­the­survival,­differentiation­and­function­of­normal­B­lymphocytes,­but­accu‐
mulating data suggest that, in the case of chronic lymphocytic leukaemia (CLL), it is 
also involved in the pathogenesis and clinical course of the disease. CLL is a malig‐
nancy of mature CD5+ CD19+ CD23+ sIgMlow B lymphocytes and is characterized by 
extremely heterogeneous clinical course, which varies from indolent to rapidly pro‐
gressive. Somatic hypermutational status of immunoglobulin heavy chain variable 
genes­(IGHV)­defines­two­CLL­subtypes,­mutated­(M‐CLL)­and­unmutated­(U‐CLL).­
U‐CLL­patients­ suffer­ from­more­ aggressive­disease,­ characterized­ by­ shorter­ time­
to treatment, progression‐free survival and overall survival in comparison to M‐CLL 
patients. Since these correlations are not dependent on the clinical stage and since 
there is no interconversion between subtypes, IGHV mutational status is currently the 
most reliable prognostic marker in CLL. Several lines of evidence indicate that both 
M‐CLL­and­U‐CLL­arise­from­an­antigen‐experienced­cell­of­origin.­Immunogenetic­
studies have revealed CLL‐biased usage of immunoglobulin variable region genes, 
as well as the existence of highly homologous, ‘stereotyped’ BCRs in CLL clones, 
strongly implying the role of antigenic drive in the development and evolution of the 
disease.
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1. Introduction
The central role that B lymphocytes play in immunity relies upon their capacity to produce 
a­vast­array­of­different­immunoglobulin­molecules­which­can­recognize­virtually­limitless­
number of foreign and autoantigens. Immunoglobulins (IG) are expressed on the surface of 
B cells as antigen‐binding component of B cell receptor (BCR), in complex with CD79A/79B 
heterodimer responsible for signal transduction. During the immune response, IG molecules 
are­secreted­as­antibodies­which­exert­different­effector­functions.­BCR­signalling­is­crucial­
for­ survival,­ proliferation­ and­differentiation­ of­ normal­ B­ lymphocytes,­ but­ has­ also­ been­
implicated in the pathogenesis of several mature B cell malignancies, including chronic lym‐
phocytic leukaemia.
Chronic lymphocytic leukaemia (CLL) manifests as clonal expansion of mature CD5+ CD19+ 
CD23+ sIgMlow B lymphocytes which gradually accumulate in blood, bone marrow and sec‐
ondary lymphoid organs [1]. It is the most frequent type of leukaemia in Western countries, 
accounting for 30–40% of all adult leukaemia cases, while it is very rare in Asian and African 
countries [2].­CLL­affects­predominantly­elderly­individuals,­aged­approximately­67–72­years­
at diagnosis, men more frequently than women [1].
CLL is characterized by extremely heterogeneous clinical presentation, with diverse therapy 
requirements and overall survival. In some patients, rapid progression and need of treatment 
occur soon after diagnosis, while others may live for decades without developing any symp‐
toms. The majority of cases, however, lie in between these extremes; the disease can follow an 
indolent course for years, but eventually turn into aggressive form.
Aetiology of CLL is still elusive. Familial clustering of CLL has been documented, implying a 
strong genetic basis of the disease. The relative risk of CLL has been estimated to be around 
eight‐fold­higher­in­first‐degree­relatives­[3]. Genome‐wide association studies have identi‐
fied­multiple­CLL­susceptibility­loci­mapping­to­genes­involved­in­apoptosis,­BCR­signalling,­
immune response and maintenance of chromosome integrity [4, 5].
A growing body of evidence indicates that CLL development and evolution result from con‐
certed action of intrinsic genetic abnormalities and extrinsic factors from the tissue microen‐
vironment, including antigens [6]. The most common chromosomal aberrations in CLL are 
deletion 13q14, trisomy 12q, deletion 11q22‐q23 and deletion 17p13, observed in approxi‐
mately 80% of patients [7]. The genes localized within minimally deleted/gained regions in 
these­aberrations­include­miR‐15a­and­miR16‐1­(del13q),­CDK4,­GLI­and­MDM2­(trisomy­12),­
ATM (del11q) and TP53 (del17p), which are involved in regulation of apoptosis and DNA 
repair [8–10].­The­recent­next‐generation­sequencing‐based­studies­have­identified­a­number­
of­recurrently­mutated­genes­in­CLL­(e.g.­NOTCH1,­SF3B1,­MYD88,­BIRC3,­NFKBIE,­TP53­
and­ATM),­predominantly­belonging­to­BCR,­toll‐like­receptor,­Notch1­and­NF‐κB­signalling­
pathways [6, 11]. In addition, genetic alterations and aberrant expression of many apoptotic 
regulators involved in both mitochondrial and death receptor apoptotic pathways have been 
described in CLL, most notably overexpression of BCL2, detected in the majority of patients 
[12–14]. However, immunogenetic studies over the past few decades have pointed to the 
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 antigenic drive on the BCR of the cell of origin as the key player, and possibly an initiating 
event, in CLL pathogenesis [15, 16].
The diversity of mechanisms involved in pathobiology of CLL cells is likely the basis of the 
clinical­ heterogeneity,­ making­ the­ prognostication­ for­ individual­ patients­ very­ difficult.­
Currently, the most important prognostic markers, widely used in routine clinical practice, 
are clinical stage (Rai and Binet) and cytogenetic aberrations [17].­In­an­attempt­to­overcome­
the clinical variability and improve the prognosis assessment, particularly in early‐stage dis‐
ease,­a­number­of­cellular­and­molecular­prognostic­markers­have­been­identified­and­vali‐
dated. Among the novel markers that have entered clinical practice (e.g. CD38 and ZAP‐70 
expression,­TP53­mutations),­the­most­powerful­one,­in­terms­of­prognosis­definition,­turned­
out to be the somatic hypermutational status of rearranged immunoglobulin heavy variable 
genes [17].
In this chapter, we will discuss the current concepts of immunoglobulin gene expression in 
chronic lymphocytic leukaemia, and its relevance for both the pathogenesis and clinical pro‐
gression of the disease.
2. Immunoglobulin gene rearrangements and the development of 
B lymphocytes
2.1. Generation of immunoglobulin diversity
Immunoglobulin (IG) molecules are heterodimers composed of two identical heavy (H) 
chains­and­ two­ identical­ light­ (L)­chains­ (κ­or­λ),­ linked­by­disulphide­bonds.­Both­heavy­
and light chains contain N‐terminal variable (V) region and C‐terminal constant (C) region 
(Figure 1a). Juxtaposed variable regions of H and L chains (VH and VL) form antigen‐binding 
site,­whose­structure­determines­the­specificity­and­the­affinity­of­immunoglobulin­molecules­
for antigens. Constant regions are not involved in antigen recognition. Heavy chain constant 
region­(CH)­defines­IG­isotypes­(IgA,­IgD,­IgE,­IgG­and­IgM)­and­mediates­effector­functions­
of antibodies. In addition, CH region is responsible for anchoring of membrane‐bound IG in 
the plasma membrane of B cells. Variable region of each IG chain consists of four relatively 
conserved framework regions (FR1, FR2, FR3 and FR4) and three hypervariable complemen‐
tarity‐determining regions (CDR1, CDR2 and CDR3). The CDR regions of H and L chains 
form six loops which create a surface that directly interacts with antigens. Heavy chain CDR3 
region (VH CDR3) exerts the highest variability and is the key determinant of antibody speci‐
ficity­[18].
IG molecules are encoded by a multitude of tandemly arranged gene segments that consti‐
tute­IGH­(heavy­chain)­locus,­IGK­and­IGL­locus­(κ­and­λ­light­chains).­Human­IGH­locus,­
located on chromosome 14q32.33, consists of four types of gene segments: V (variable), D 
(diversity),­J­(joining)­and­C­(constant),­in­5′–3′­orientation.­There­are­38–46­functional­IGHV­
gene­segments,­which­can­be­divided­into­6–7­subgroups­based­on­sequence­homology,­23­
functional­ IGHD­gene­segments,­6­ functional­ IGHJ­gene­segments­and­9­ functional­ IGHC­
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gene segments (Figure 2).­Light­chain­loci,­on­the­other­hand,­lack­D­segments.­Human­IGK­
locus­(chromosome­2p11.2)­contains­a­cluster­of­34–38­functional­IGKV­gene­segments­which­
belong­ to­ 5­ subgroups,­ followed­ by­ 5­ IGKJ­ gene­ segments­ and a single C gene segment. 
Human IGL locus (chromosome 22q11.2) is composed of 29–33 functional IGLV gene seg‐
ments, divided into 10 subgroups, and 4–5 functional IGLJ‐IGLC tandems [20]. Allelic vari‐
ants of many gene segments exist, particularly in the IGH locus. It should be noted that the 
actual number of gene segments in all three loci is much higher, due to the presence of pseu‐
dogenes and ORFs (open reading frames). In addition, the number of functional gene seg‐
ments in a locus depends on the haplotype, since some genes can be inserted or deleted, or 
can be functional or pseudogene, depending on the allele.
Figure 1. Schematic representation of an immunoglobulin molecule. (a) IG molecules consist of two identical heavy (H) 
chains and two identical light (L) chains. Both H and L chains contain variable region (VH and VL, respectively) and 
constant region (CH and CL, respectively). VH region is encoded by rearranged V, D and J gene segments, while VL 
is encoded by rearranged V and J gene segments. (b) VH region consists of four framework regions (VH FR1, VH FR2, 
VH FR3 and VH FR4) and three hypervariable complementarity‐determining regions (VH CDR1, VH CDR2 and VH 
CDR3). VH FR1‐3, VH CDR1 and VH CDR2 are encoded entirely by IGHV gene segment; VH FR4 is encoded by IGHJ 
gene segment. VH CDR3 is positioned at the IGHV‐IGHD‐IGHJ junction, and comprises amino acids between conserved 
cysteine (codon 104) in FR3 and conserved tryptophan (codon 118) in FR4 [19]. N1 and N2 regions are being created via 
random addition and deletion of nucleotides during IGHV‐IGHD and IGHD‐IGHJ joining.
Lymphocyte Updates - Cancer, Autoimmunity and Infection52
Immunoglobulin variable region is being generated by somatic recombination between V, 
D and J gene segments (H chains) and V and J gene segments (L chains), which occur dur‐
ing­differentiation­ of­ B­ lymphocytes.­At­ the­ IGH­ locus,­which­ rearranges­ before­ IGL­ loci,­
the­first­recombination­event­joins­one­of­the­IGHD­gene­segments­to­one­of­the­IGHJ­gene­
segments, and the sequence between the rearranged genes is being deleted. The obtained 
IGHD‐IGHJ rearrangement then recombines with one of the IGHV gene segments, leading to 
the formation of complete IGHV‐IGHD‐IGHJ rearrangement which will be fused to an IGHC 
gene­(Cμ­or­Cδ)­during­RNA­splicing­and,­ultimately,­expressed­at­the­cell­surface­as­IgM­or­
IgD. Productive rearrangement of one IGH locus inhibits the rearrangement of IGH locus on 
the­other­chromosome­(allelic­exclusion),­thus­ensuring­the­monospecificity­of­B­lymphocyte­
[22]. However, if the rearrangement of one allele is unproductive, the other one will undergo 
recombination and, if the second rearrangement fails, the cell will die by apoptosis. Similar 
recombination­process­occurs­between­V­and­J­gene­segments­at­the­light­chain­loci.­IGK­locus­
rearranges­before­IGL;­successful­recombination­at­one­IGK­allele­inhibits­the­rearrangement­
of the other one (allelic exclusion), as well as the rearrangement of IGL loci (isotypic exclu‐
sion).­Alternatively,­unproductive­ rearrangement­of­one­ IGK­ locus­ leads­ to­ recombination­
of the other allele and, if unsuccessful, the IGL locus will rearrange. Once again, if neither of 
the­attempts­results­in­productive­light­chain­rearrangement,­the­cell­will­undergo­apoptosis.
Figure 2. Schematic­representation­of­the­human­IGH­locus­(not­to­scale).­Human­IGH­locus­contains­38–46­functional­
IGHV­gene­segments,­23­functional­IGHD­gene­segments,­6­functional­IGHJ­gene­segments­and­9­functional­IGHC­gene­
segments. IGHV gene segments are designated by a number for the subgroup, followed by an hyphen and a number for 
the­localization­in­the­locus,­in­the­3′–5′­direction;­IGHD­and­IGHJ­gene­segments­are­numbered­in­the­opposite­direction­
(5′–3′)­[21]. Only functional genes are depicted.
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Given the number of germline gene segments that can recombine at IG loci, as well as random 
pairing of heavy and light chains, it is clear that B lymphocytes can produce a vast number of 
different­antibodies­(‘combinatorial­diversity’).­However,­the­actual­number­of­combinations­is­
lower than the theoretical estimate of ∼1.6­×­106, since not all gene segment recombinations occur 
with the same frequencies and not all IGH‐IGL pairs are functional. In addition, it has been 
shown that V(D)J recombinations are not a stochastic process, but are determined by genetic 
factors and are regulated during ontogeny [23].
The diversity of the primary antibody repertoire (the repertoire of naïve B cells) is further 
increased by ‘junctional diversity’. The process of somatic recombination is catalysed by several 
enzymes jointly called V(D)J recombinase and, although very precise, their action introduces 
variability at the junctions of V, (D) and J gene segments. Recombination is enabled by the pres‐
ence­of­conserved­recombination­signal­(RS)­sequences­which­flank­3′­end­of­V­genes,­5′­end­of­
J genes and both ends of D genes. RS sequences, recognized by recombination activating gene 
1 and 2 (RAG1 and RAG2) enzymes, ensure that light chain V genes can rearrange only with 
J genes, while IGHV genes can rearrange only with IGHD, and IGHD only with IGHJ genes. 
During this process, trimming of the ends of recombining gene segments by exonucleases 
occurs, as well as the addition of short palindromic sequences and non‐templated nucleotides 
(the­latter­catalysed­by­terminal­deoxynucleotidyl­transferase,­TdT)­[24]. The random addition 
and deletion of nucleotides during IGHV‐IGHD and IGHD‐IGHJ ligation creates two N regions 
(N1 and N2), and is the source of the extreme variability of VH CDR3, which is positioned at the 
VDJ junction (Figure 1b). Diversity of VH CDR3 in both length and amino acid sequence results 
in the production of much larger IG repertoire than it would be generated solely by combining 
germline gene segments (up to 1011­different­IGs).
Diversification­of­ immunoglobulins­continues­after­antigen­encounter­(secondary­antibody­
repertoire) via somatic hypermutations and class‐switch recombination, generating B lym‐
phocytes­with­enormously­wide­range­of­specificities­(see­next­section).
2.2. B cell differentiation
B­cell­differentiation­is­a­multi‐step­process­which­can­be­divided­into­two­phases:­antigen‐­
independent phase, taking place in bone marrow (and fetal liver), followed by antigen‐ 
dependent phase in secondary lymphoid organs.
The­first­stage­of­B­cell­development­in­bone­marrow­is­early­pro‐B­cell,­defined­by­the­begin‐
ning of IGHD‐IGHJ recombinations. Joining of IGHV gene to IGHD‐IGHJ rearrangement 
occurs in late pro‐B cells and leads to transcription and synthesis of μ heavy chain, which 
contains­IGHV‐IGHD‐IGHJ­complex­attached­to­Cμ.­The­expression­of­μ­heavy­chain­defines­
the large pre‐B cell stage. The μ chain is predominantly cytoplasmic, but it can associate with 
surrogate light chains and, in complex with CD79A/CD79B, is transiently expressed at the 
cell surface as the pre‐BCR. Subsequently, the cell enters the small pre‐B stage in which rear‐
rangements of light chain loci occur, enabling pairing of previously synthesized μ chain with 
IGK­or­IGL­and,­thus,­assembly­of­IgM.­Expression­of­surface­IgM,­as­a­part­of­BCR,­marks­the­
immature­B­cell.­At­this­stage,­self‐reacting­clones­are­being­eliminated,­or­their­specificities­
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may be changed via receptor editing and IGHV replacement [25]. Immature B cells migrate 
to the spleen where they become mature naïve B cells. As a result of alternative splicing of 
IGH­transcripts,­which­joins­IGHV‐IGHD‐IGHJ­gene­to­either­Cμ­or­Cδ,­these­cells­coexpress­
membrane‐bound­IgM­and­IgD­with­the­same­antigen­specificity.
Naïve B lymphocytes reside in secondary lymphoid organs (spleen, lymph nodes and 
mucosal­ lymphoid­ tissues)­where­ they­ encounter­various­ antigens.­Engagement­of­BCR­
with­ a­ specific­ antigen­ gives­ rise­ to­ a­ cascade­ of­ signalling­ events­ that­ activate­ B­ cell,­
leading­to­proliferation­of­antigen‐specific­clone­and,­ultimately,­differentiation­into­anti‐
body‐secreting plasma cells and memory cells. Based on the requirement for T cell help in 
activation of B lymphocytes, two types of response to antigen stimulation exist. Bacterial 
polysaccharides and lipopolysaccharides can directly activate B cells (T cell‐independent 
response), resulting in rapid IgM production. In contrast, the response to protein antigens 
is T cell‐dependent and requires the interaction of B cells with CD4+ T cells and antigen‐
presenting­cells.­Upon­T­cell‐mediated­activation,­proliferating­B­cells­migrate­deep­into­
lymphoid follicle, forming the structure called germinal centre. In a highly specialized 
microenvironment of germinal centres, B cells start to proliferate at high rate and undergo 
somatic hypermutations and class‐switch recombination [26].
The process of somatic hypermutation (SHM), mediated by activation‐induced cytidine 
deaminase (AID), introduces point mutations into the rearranged immunoglobulin loci at 
a rate 106 times higher than the spontaneous mutation rate of other genes. The single base 
substitutions are localized in the variable region of heavy and light chains, while the constant 
region­remains­unaffected.­They­are­preferentially­targeted­to­specific­hotspot­motifs­(RGYW­
and its inverse repeat WRCY), with transitions predominating over transversions, and accu‐
mulate in both FRs and CDRs [27]. Replacement mutations tend to be clustered in CDRs, since 
they­alter­the­affinity­of­IGs­to­antigens.­In­FRs,­on­the­other­hand,­replacement­mutations,­
which could disrupt the basic IG architecture, are counter‐selected, and silent mutations are 
more frequent. The somatic hypermutation process can also introduce small insertions or 
deletions,­although­this­is­a­rare­event­created­by­a­mechanism­different­than­AID‐mediated­
SHM.
Accumulation of somatic hypermutations generates clonal progeny of activated B cell with 
diversified­IG­rearrangements­and,­hence,­different­affinity­for­antigen.­These­cells­are­subse‐
quently­subjected­to­selection­by­antigen:­B­cells­that­efficiently­recognize­antigen­presented­
by follicular dendritic cells receive survival signals, provided by BCR engagement and T cell 
co‐stimulation, and continue to proliferate, while B cells that do not bind antigen or bind it 
with­low­affinity­die­by­apoptosis.­Multiple­rounds­of­proliferation,­somatic­hypermutation­
and­selection­result­in­affinity­maturation,­i.e.­production­of­B­lymphocytes­with­increasing­
specificity­and­affinity­for­antigen.­Along­with­affinity­maturation,­the­cells­undergo­class‐
switch recombination (also mediated by AID), which leads to fusion of IGHV‐IGHD‐IGHJ 
rearrangement to a downstream constant gene segment. This enables production of isotypes 
other­than­IgM­and­IgD,­but­with­the­same­antigen­specificity­[28]. Antigen‐selected B cells 
ultimately­exit­the­germinal­centre­and­finalize­their­differentiation­into­high‐affinity­antigen‐
specific­plasma­cells­and­memory­cells,­with­specific­effector­functions.
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Somatic hypermutations and class‐switch recombination further enhance immunoglobulin 
variability and, in combination with other sources of diversity (combinatorial and junctional 
diversity), enable formation of up to 1012­possible­antibody­specificities­ [20]. The potential 
of B cells to create such a huge IG repertoire, however, comes at a high cost since it causes 
a­considerable­wastage­of­cells­along­the­pathway­of­their­differentiation.­The­mechanisms­
responsible for variability of immunoglobulin rearrangements can also render them unpro‐
ductive due to recombination of non‐functional pseudogenes, out‐of‐frame junctions, genera‐
tion of stop codons at the junctions, as well as introduction of frameshifts and stop codons by 
SHM. In addition, replacement mutations induced by SHM process can impair the structure 
of­immunoglobulin­molecule­or­lower­its­affinity­for­antigen.­As­mentioned­above,­B­cells­that­
fail to generate productive heavy‐ and light chain rearrangements and produce functional 
antibodies undergo apoptotic cell death.
3. Immunoglobulin gene rearrangements in CLL
3.1. IGHV mutational status
The extreme clinical heterogeneity of chronic lymphocytic leukaemia has inspired an exten‐
sive search for molecular and cellular markers with the prognostic and predictive value. 
Immunoglobulin rearrangements of CLL clones were brought into the spotlight upon the 
findings­ that,­ in­ around­ 50%­ of­ CLL­ patients,­ heavy­ chain­ rearrangements­ carry­ somatic­
hypermutations,­and­that­SHM­status­of­rearranged­IGHV­genes­significantly­correlates­with­
the clinical course of the disease. Patients with unmutated IGHV‐IGHD‐IGHJ rearrange‐
ments are usually in advanced clinical stages, have progressive disease, atypical morphology 
and require chemotherapy soon after diagnosis. In contrast, patients with mutated IGHV‐
IGHD‐IGHJ rearrangements predominantly present with non‐progressive disease, typical 
morphology,­require­no­or­minimal­chemotherapy­and­have­significantly­longer­time­to­first­
treatment, progression‐free survival and overall survival [29–33]. These correlations have 
been­confirmed­in­multiple­studies,­and­today,­it­is­widely­accepted­that­CLL­can­be­divided­
into­two­subtypes,­mutated­(M‐CLL)­and­unmutated­(U‐CLL),­with­different­clinical­outcome.­
The IGHV mutational status turned out to be the strongest independent prognostic marker 
whose value, inter alia, lies in the fact that it does not change over time and that it can predict 
the clinical behaviour of CLL at the time of diagnosis as well as at any stage of the disease 
(i.e. regardless of the tumour burden).
The­cut‐off­level­that­is­being­in­use­for­distinguishing­M‐CLL­from­U‐CLL­is­98%­of­identity­
between the rearranged IGHV gene and its germline counterpart (calculated from codon 1 to 
codon­104);­cases­with­≥98%­identity­are­considered­unmutated,­while­those­with­<98% iden‐
tity are considered mutated [34, 35].­This­cut‐off­has­originally­been­chosen­in­order­to­elimi‐
nate the possibility of interpreting allelic polymorphisms as somatic mutations. Although in 
some­studies­other­cut‐off­values­(97%­and­95%)­allowed­better­separation­of­the­two­prognos‐
tic groups, 2% of somatic mutations are generally accepted as the best discriminator between 
mutated and unmutated cases [36–38]. However, since this level of mutations is an arbitrary 
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cut‐off,­the­caution­is­recommended­when­interpreting­the­prognostic­implications­in­cases­
with the borderline mutational status [34]. Indeed, it has been demonstrated that the group 
of patients with the borderline mutated rearrangements (97–97.9% identity) comprised cases 
with both poor and good prognosis [38, 39]. In addition, sequencing of the unrearranged IGH 
genes in patients with high percentage of identity (98–99.6%) revealed that the divergence 
of rearranged IGHV gene from the closest germline gene, even in this group, is actually due 
to somatic hypermutation, further underscoring the statistical, rather than biological ratio‐
nale­for­the­98%­cut‐off­[40].­However,­the­fact­that­median­survival­does­not­differ­between­
patients with 100% and those with 99% or 98%,­but­is­significantly­shorter­in­comparison­to­
survival of patients with <98% identity, justifies­the­application­of­98%­cut‐off­in­clinical­prac‐
tice [39]. Finally, it should be noted that the absence of correlation between IGHV mutational 
status­and­the­prognosis­in­a­proportion­of­patients­can­be­attributed,­at­least­in­some­cases,­
to­other­factors­that­influence­the­clinical­outcome­(see­below).
Besides the borderline cases, clinical prognostication can be challenging in cases carrying 
double IGHV‐IGHD‐IGHJ rearrangements. In the majority of these cases only one rearrange‐
ment is productive, but in rare instances (up to 5% of cases), double productive rearrange‐
ments can be detected [41, 42].­Expression­of­double­productive­rearrangements­may­be­the­
result of the lack of allelic exclusion, which has been described in CLL B cells or, alterna‐
tively,­double­(or­multiple)­productive­rearrangements­originate­from­different­CLL­clones­
[41, 43]. If both rearrangements are of the same mutational status, prognostic interpretation is 
straightforward regardless of whether both or just one rearrangement is productive. The cases 
with productive mutated and unproductive unmutated IGHV‐IGHD‐IGHJ rearrangements 
are considered mutated, since the productive rearrangement is relevant for the biology of CLL 
cells. However, if double productive rearrangements are of discordant mutational status or 
if unmutated rearrangement is productive while the mutated rearrangement is unproductive 
(implying that the cell has undergone the SHM process), the clinical implications currently 
cannot be predicted [44].
The association of IGHV mutational status with other prognostic markers in CLL has been 
extensively­studied.­Besides­the­contribution­to­better­understanding­of­the­disease­biology,­
the­ research­ also­ aimed­ at­ finding­ a­ potential­ surrogate­marker­ that­ could­ substitute­ the­
effortful­IGHV­mutational­analysis­in­clinical­practice.­The­four­most­frequent­clonal­chro‐
mosomal aberrations (del13q, del11q, trisomy 12q and del17p) represent strong independent 
prognostic­markers­and­are­differentially­distributed­between­M‐CLL­and­U‐CLL­[7, 45, 46]. 
The aberrations with adverse prognostic impact (del11q, trisomy 12q and del17p) are asso‐
ciated predominantly with unmutated IGHV‐IGHD‐IGHJ rearrangements, while favour‐
able del13q is more frequent in mutated cases [36, 37, 47–49]. Furthermore, unmutated CLL 
subtype is characterized by high risk of acquiring adverse chromosomal aberrations during 
the disease course [50]. In contrast to cytogenetic abnormalities, the association of CD38 and 
ZAP‐70 with IGHV mutational status is less consistent. The expression of CD38 on the sur‐
face of >30% of leukemic cells is an independent negative prognostic factor associated with 
the­progressive­disease,­shorter­time­to­first­treatment­and­shorter­overall­survival,­although­
the level of expression may vary over time [29, 51–53]. In some studies, CD38 positivity was 
strongly correlated to unmutated IGHV status, while others failed to detect any association, 
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regardless­of­the­cut‐off­level­used­for­defining­CD38­status­[29, 36, 49, 54]. Similarly to CD38, 
the expression of zeta‐chain‐associated protein kinase 70 (ZAP‐70) is also independent nega‐
tive prognostic marker associated with adverse clinical characteristics and poor prognosis 
[55–59]. Initially, in many studies, ZAP‐70 was found to be expressed predominantly in 
unmutated CLL and was suggested as a surrogate marker for IGHV mutational status; how‐
ever, subsequent research revealed a substantial discordance between these two markers [49, 
55, 57, 60–63].
The expression of several other genes has been reported to exert a strong prognostic value, 
qualifying them as potential biomarkers. Among those RNA‐based markers, lipoprotein 
lipase (LPL) emerged as the most powerful one, whose high expression level correlates with 
advanced­clinical­stage,­shorter­time­to­first­treatment­and­overall­survival,­as­well­as­with­
other adverse prognostic parameters (short lymphocyte doubling time, ZAP‐70 and CD38 
positivity, poor‐risk cytogenetics) [64–70]. Moreover, LPL expression turned out to be a 
potent predictor of IGHV mutational status, as high levels of LPL were found to be strongly 
associated with unmutated IGHV‐IGHD‐IGHJ rearrangements [55, 60, 64–67, 71].
To conclude, despite certain limitations, IGHV mutational status analysis is currently the 
golden standard for CLL prognostication, which has been introduced into clinical practice in 
many centres. It is integrated into the most advanced prognostic scoring systems suggested 
for­risk­stratification­of­CLL­patients­[72–75].
3.2. Immunoglobulin variable region gene repertoire in CLL
The analyses of immunoglobulin heavy chain rearrangements in CLL revealed that not only 
IGHV, IGHD and IGHJ gene usage in CLL B lymphocytes is distinct from that of normal 
peripheral­blood­B­cells,­but­also­the­gene­repertoires­of­U‐CLL­and­M‐CLL­clones­signifi‐
cantly­differ.
The most commonly used IGHV subgroup in CLL rearrangements is IGHV3 (as is the case 
with normal B cells), followed by IGHV1 and IGHV4. However, the comparison of IGHV 
subgroup­usage­between­CLL­and­normal­B­cells­showed­that­there­is­a­significant­over‐rep‐
resentation of IGHV1 subgroup, as well as underrepresentation of IGHV3 subgroup in CLL 
[33, 76–80].­ In­ addition,­ the­ frequencies­ of­ IGHV­ subgroups­ are­ different­ in­ the­ two­CLL­
subtypes:­IGHV1­genes­are­present­predominantly­in­the­rearrangements­of­U‐CLL­clones,­
in contrast to IGHV3 and IGHV4 genes that predominate in M‐CLL clones. Moreover, a hier‐
archy in the SHM level among IGHV subgroups has been documented: IGHV3 and IGHV4 
genes show a high mutational load while IGHV1 genes carry very few mutations (IGHV3 > 
IGHV4 > IGHV1) [30, 33, 80].
A strong bias in usage of individual IGHV genes has also been detected. In most studies, only 
6–7­IGHV­genes­were­utilized­in­more­than­50%­of­CLL­IGHV‐IGHD‐IGHJ­rearrangements.­
The­most­frequently­used­IGHV­genes­were­IGHV1‐69,­IGHV3‐23,­IGHV3‐7­and­IGHV4‐34,­
followed by several others (IGHV3‐30, IGHV3‐30.3, IGHV3‐48, IGHV1‐2, IGHV1‐3, 
IGHV1‐18, IGHV4‐39 and IGHV4‐59), depending on the cohort [30, 33, 79–82]. It should be 
noted, though, that normal B cell repertoire is not random, and that certain genes (such as 
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IGHV3‐23, IGHV3‐7 and IGHV3‐30.3) are overused [76]. Hence, some of the most common 
IGHV genes in CLL are represented with frequencies similar to those of normal B cells [33, 76, 
79].­However,­CLL‐related­over‐representation­of­IGHV1‐69­has been consistently reported, 
as well as its predominance in unmutated rearrangements. On the other hand, IGHV3‐23, 
IGHV3‐7, IGHV4‐34 and IGHV3‐48 are the most frequently used genes in mutated rearrange‐
ments.­The­differences­in­the­mutational­load,­observed­for­IGHV­subgroups,­are­even­more­
evident­when­ individual­genes­ are­ considered.­For­ example,­ IGHV1‐69­gene­usually­har‐
bours no or just a few somatic mutations, whereas IGHV3‐7, IGHV3‐23 and IGHV4‐34 genes 
are highly mutated [30, 33, 78–80, 82].
The­majority­ of­ CLL­ IGHV‐IGHD‐IGHJ­ rearrangements­ contain­ IGHJ4­ and­ IGHJ6­ genes;­
IGHJ6­gene­is­predominantly­used­in­unmutated­rearrangements,­in­contrast­to­IGHJ4,­which­
is­over‐represented­in­mutated­rearrangements.­Since­IGHJ6­ is­ the­ longest­ IGHJ­gene,­ this­
results­in­significantly­longer­median­VH­CDR3­lengths­of­unmutated­vs.­mutated­rearrange‐
ments [30, 33, 80].
Besides the biased usage of IGH subgroups and individual genes in CLL, early studies of 
CLL immunoglobulin repertoire have also revealed the over‐representation of certain IGHV‐
IGHD‐IGHJ­combinations.­For­example,­IGHV1‐69­was­frequently­found­in­combination­with­
IGHJ6­and­IGHD3‐3­or­IGHD2‐2,­creating­VH­CDR3­longer­than­the­average,­which­is­not­
common in rearrangements of normal B cells [33, 83, 84]. In contrast, the majority of IGHV3‐7 
genes were found to be combined with IGHJ4 and IGHD3 yielding shorter VH CDR3, while 
IGHV4‐34­was­associated­with­both­IGHJ4­and­IGHJ6­genes­[33].­These­findings­pointed­to­
the CLL‐biased VH CDR3 features and laid the foundations of the stereotyped B cell receptor 
concept (see below).
Geographical­and­ethnical­differences­in­IGHV­gene­usage­in­CLL­rearrangements­have­also­
been reported [79, 82, 85–89]. For example, IGHV3‐21 gene has been detected in IGHV‐IGHD‐
IGHJ rearrangements of more than 11% of Scandinavian patients, while it was less frequent 
in­the­UK­(7.9%)­and­very­rare­in­Mediterranean­cohorts­(less­than­3%­of­cases)­[79, 90–93]. In 
addition, IGHV1 genes have been shown to be represented with lower and IGHV4 genes with 
higher frequencies in CLL clones of patients from Asian countries in comparison to patients 
from Western populations [94–96].
The light chain variable region gene repertoire in CLL has been substantially less studied 
but, nevertheless, some similarities with the repertoire of heavy chains have been observed. 
The­ratio­of­expressed­κ­and­λ­light­chains­in­CLL­B­lymphocytes­mirrors­that­of­normal­B­
cells (2:1) [97].­As­is­the­case­with­IGH­rearrangements,­roughly­50%­of­IGK/IGL­rearrange‐
ments belong­to­the­mutated­subtype­­and,­in­most­cases,­­IGH­and­IGK/IGL­rearrangements 
are of the same mutational status [98].­A­skewed­usage­of­IGKV/IGLV­and­IGKJ/IGLJ­sub‐
groups and individual genes has been reported, but the interpretations of whether their rela‐
tive­frequencies­differ­from­those­of­normal­B­cells­are­discrepant,­probably­due­to­different­
normal control datasets used for comparison. Similar to IGHV, the distribution of individual 
IGKV­and­ IGLV­genes­between­mutated­and­unmutated­ rearrangements­ is­ asymmetrical­
and,­for­some­genes,­CLL‐biased.­In­addition,­certain­IGKV‐IGKJ­and­IGLV‐IGLJ­combina‐
tions are over‐represented and CLL‐related [97–99]. Importantly, non‐stochastic pairing of 
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heavy and light chains has been detected and shown to depend on VH CDR3 motifs [100]. 
Since­preferential­pairing­of­specific­IGHV­and­IGKV­or­IGLV­genes­has­not­been­observed­
in normal B cell repertoire, biased usage of certain VH CDR3/VL CDR3 associations strongly 
implies­that­the­expression­of­BCRs­with­specific­antigen‐binding­characteristics­is­favoured­
in CLL [101, 102].
The usage of particular IGHV genes has been found to correlate with clinical course of CLL. 
The most striking example is IGHV3‐21 gene, which emerged as an adverse prognostic factor 
regardless of the IGHV mutational status. IGHV3‐21 is expressed in both CLL subtypes, but 
predominantly in M‐CLL. However, median overall survival of patients expressing mutated 
IGHV3‐21­ rearrangements­ was­ found­ to­ be­ significantly­ shorter­ than­median­ survival­ of­
non‐IGHV3‐21 mutated patients, and comparable to the survival of unmutated cases [90, 91, 
103, 104]. Other IGHV genes also exhibited association with certain clinical characteristics; 
for example, IGHV3‐23 has been indicated as a marker of worse prognosis within M‐CLL 
subtype, IGHV3‐72 is over‐represented in highly stable CLL, and IGHV3‐30 has been linked 
to spontaneous regression [105–107]. The associations of IG repertoire with clinicobiological 
features of CLL will be further discussed in the next section, in the context of BCR stereotypy.
3.3. BCR stereotypy
The discovery that CLL includes patients with both mutated and unmutated IGHV‐IGHD‐
IGHJ­rearrangements­was­the­first­evidence­pointing­towards­the­role­of­antigens­in­the­patho‐
genesis of the disease. The presence of somatic hypermutations and higher replacement/silent 
mutations (R/S) ratio in VH CDRs than in FRs indicate that M‐CLL cells have undergone 
germinal centre reactions and been selected by T cell‐dependent antigen [33]. Consequently, 
due­to­the­lack­of­SHM­in­IGH­rearrangements,­U‐CLL­cells­have­initially­been­thought­to­
originate­from­naïve­B­lymphocytes.­However,­further­studies­revealed­that­both­U‐CLL­and­
M‐CLL cells express highly restricted, non‐random immunoglobulin repertoire. CLL‐biased 
representation of certain IGHV genes and IGHV‐IGHD‐IGHJ combinations, as well as VH 
CDR3 characteristics, implies the recognition of limited set of antigens, suggesting that CLL 
clones,­both­mutated­and­unmutated,­derive­from­activated­B­cells.­In­the­case­of­U‐CLL,­the­
cell of origin could have been activated either by T cell‐independent antigens and autoanti‐
gens outside germinal centres or by antigens that select against SHM [108]. High R/S ratio in 
VH­CDR3­of­minimally­mutated­U‐CLL­rearrangements­(<2%­mutations)­further­argues­in­
favour­of­an­antigen‐driven­process,­since­even­a­single­mutation­can­significantly­enhance­
antigen‐binding­affinity­of­BCR­and,­hence,­be­selected­for.­In­keeping­with­these­observa‐
tions,­studies­of­gene­expression­profiles­and­surface­phenotypes­showed­that­both­M‐CLL­
and­U‐CLL­cells­exhibit­characteristics­of­antigen‐experienced­B­lymphocytes­[60, 109, 110]. 
Finally, the most compelling evidence for the involvement of antigen in the development of 
CLL comes from the discovery of ‘stereotyped’ B cell receptors.
Following­the­initial­findings­on­IG­gene­repertoire­and­VH­CDR3­restrictions,­ it­has­been­
observed in multiple studies that a proportion of unrelated CLL patients expresses highly 
homologous, almost identical BCRs (stereotyped BCRs) [42, 79, 82, 85, 111–115]. Stereotyped 
BCRs­have­been­detected­in­both­CLL­subtypes,­although­with­higher­frequency­in­U‐CLL.­
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Closely related BCRs have been clustered into stereotyped subsets. With the increase in the 
number­of­cases­investigated­in­these­studies,­the­number­of­identified­stereotyped­subsets­
grew larger, reaching several hundreds. However, the proportion of cases which could be 
assigned to stereotyped subsets did not exceed ∼30%, regardless of the cohort size [116]. In 
the largest study conducted by now, which included >7000 CLL patients, 19 subsets accounted 
for 41% of the stereotyped cases (major subsets) and 12% of the total cohort; other stereotyped 
subsets accounted for 18% of cases, while the remaining 70% of cases were heterogeneous, 
i.e. did not belong to any of the stereotypes [115].
The­required­criteria­initially­adopted­for­stereotyped­subset­definition­included­the­usage­
of the same IGHV, IGHD and IGHJ gene and IGHD reading frame, as well as identity of 
VH­CDR3­amino­acid­ sequence­≥60%­ [111, 113]. However, it soon became apparent that 
different­IGHV­genes­(although­with­substantial­sequence­similarity)­could­generate­highly­
homologous VH CDR3s if recombined with the same IGHD and IGHJ genes. In addition, 
introduction of somatic hypermutations could lead to convergence of VH CDR3 sequences 
encoded­by­different­IGHV­genes­[115, 117]. Therefore, a revised set of criteria for cluster‐
ing of IGH rearrangements into stereotyped subsets has been developed, which included 
additional parameters: (1) the presence of IGHV genes of the same phylogenetic clan, (2) 
identical VH CDR3 length and a unique amino acid motif at the exact position within VH 
CDR3, (3) VH CDR3 amino acid identity >50% and similarity > 70% [115]. Conserved amino 
acid­motifs­which­ define­ a­ subset­ can­ encompass­ almost­ the­ entire­ VH­CDR3­ sequence­
(e.g.­ subset­ #6­and­#10)­or,­ alternatively,­ can­ involve­ just­ a­ few,­or­ even­ just­one,­ critical­
amino acid residue (e.g. subset #2). Furthermore, in some subsets, the conserved motifs are 
encoded­solely­by­specific­IGHD‐IGHJ­combinations­(e.g.­subsets­#3,­#5­and­#8),­while­ in­
others, conserved amino acids are located in junctional N1 and N2 regions (e.g. subsets #4, 
#16,­#77­and­#201)­[115]. The strong bias in usage of individual IGHV genes in stereotyped 
BCRs­has­been­detected,­since­only­a­few­genes­(IGHV1‐69,­IGHV1‐2,­IGHV1‐3,­IGHV3‐21,­
IGHV4‐34 and IGHV4‐39) are expressed in around 80% of clustered cases, while IGHV3‐7, 
IGHV3‐23, IGHV3‐30 and IGHV3‐33, though frequent in CLL, are virtually absent from 
stereotyped subsets [117]. In addition, the majority of subsets exhibit restricted light chain 
usage­with­subset‐biased­κ­and­λ­CDR3­motifs,­thus­evidencing­the­significant­role­of­light­
chains­in­antigen‐binding­specificities­of­stereotyped­BCRs­[118]. Most of the major subsets 
are characterized by exclusively mutated or unmutated rearrangements, while several of 
them­(e.g.­subset­#1,­#2­and­#99)­can­be­detected­among­both­M‐CLL­and­U‐CLL­clones­[115, 
117]. Characteristics of the most frequent among major stereotyped subsets are depicted in 
Table 1.
Extensive­research­on­BCR­stereotypy­revealed­the­consistent­association­of­certain­stereo‐
typed subsets with clinicobiological features of patients. It is well known that proliferation 
and survival of CLL cells rely on BCR signalling, along with signalling via other surface 
receptors which transduce signals from the microenvironment, since they rapidly undergo 
apoptosis when cultivated in vitro [16, 119].­The­differences­in­aggressiveness­of­M‐CLL­and­
U‐CLL­clones­have­been­attributed,­at­least­in­part,­to­their­different­BCR­signalling­capacity;­
CLL cells with unmutated BCRs have been shown to respond more avidly to sIgM cross‐
linking and express higher levels of BCR target genes than M‐CLL cells, which are more 
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Subset Mutational status IGHV IGHD IGHD RF IGHJ VH CDR3 length VH CDR3 pattern* IGKV/IGLV
#1 mostly­U V1/5/7 D6‐19 3 J4 13 AR.[NQ]W[AVLI]....FD. KV1‐39 
KV1D‐39
#2 mostly M V3‐21 no D J6 9 [AVLI].[DE]…M[DE]. LV3‐21
#3 U V1‐69 D2‐2 3 J6 22 A…..[AVLI][AVLI]V..A….YYGMD. Variable
#4 M V4‐34 D5‐5  
D4‐17  
D3‐10
1
3
3
J6 20 [AVLI]RG…….[KRH]RYYYYG.[DE]. KV2‐30
#5 U V1‐69 D3‐10 3 J6 20 AR……[AVLI]…YYYY.MD. Variable
#6 U V1‐69 D6‐13 2 J3 21 ARGG.YDY[AVLI]WGSYR..[DE][AVLI]FD. KV3‐20
#8 U V4‐39 D6‐13 1 J5 19 A….YSSSW….NWFDP KV1‐39 
KV1D‐39
Subset­#2­is­the­most­frequent­stereotyped­subset,­followed­by­subset­#1,­#4,­#6,­#5,­#3­and­#8­[115].
*A dot represents any amino acid at a given position; a pair of square brackets represents one amino acid position and any of the enclosed amino acids can be found at that 
position.­Abbreviations:­M­=­mutated;­U­=­unmutated;­and­RF­=­reading­frame.
Table 1. The most common major stereotyped subsets.
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anergic [120–123].­However,­it­has­been­observed­that­patients­belonging­to­specific­stereo‐
typed­­subsets­­follow­different­clinical­course­from­patients­assigned­to­other­subsets,­even­
if expressing the same IGHV gene and having the same IGHV mutational status [82, 93, 124, 
125]. The culprit for these subset‐related clinical distinctions could be the stereotyped BCR 
itself,­ since­differences­ in­ antigen­ reactivity­ and­ signalling­ capacity­ of­BCRs­belonging­ to­
certain subsets have been detected. For example, it has been demonstrated that subset #1 
and­#2­primary­B­cells­were­significantly­less­responsive­to­antigenic­stimulations­in vitro in 
comparison to subset #8 cells [126].­Additionally,­subset‐specific­distribution­of­prognosti‐
cally­significant­chromosomal­aberrations­(del13q,­del11q,­trisomy­12q­and­del17p),­as­well­
as recurrent mutations in frequently mutated genes in CLL (TP53, BIRC3, MYD88, NOTCH1 
and­SF3B1)­has­been­reported,­further­underscoring­the­differences­between­stereotyped­sub‐
sets [127, 128].
As­mentioned­in­the­previous­section,­the­usage­of­IGHV3‐21­gene­has­been­identified­as­a­
factor of poor prognosis independent of IGHV mutational status in several studies. However, 
subsequent research revealed that this was only true for a proportion of cases, which turned 
out to belong to subset #2. Subset #2 (IGHV3‐21/IGLV3‐21) is the largest among stereotyped 
subsets,­ detected­ in­ both­ U‐CLL­ and­ M‐CLL,­ and­ associated­ with­ del11q,­ del13q,­ CD38­
expression and SF3B1 mutations [124, 127, 128]. It has been found that IGHV3‐21‐utilizing 
cases assigned to subset #2, whether mutated or not, follow an aggressive clinical course, 
while cases carrying IGHV3‐21 in heterogeneous BCRs have variable clinical course which 
correlates to IGHV mutational status [79, 85, 129].
Subset­#1­(IGHV1/5/7/IGKV1(D)‐39)­is­the­second­largest­stereotyped­subset,­mostly­unmu‐
tated, and also associated with aggressive disease and adverse prognosis. Recent studies 
revealed­a­significant­enrichment­for­TP53­defects­(del17p­and/or­TP53­mutations),­trisomy­
12q and NOTCH1 mutations [128, 130]. In addition, subset #1 B cells exhibited higher pro‐
liferation rate following in vitro BCR ligation with anti‐IgM antibodies than non‐subset #1 
unmutated B cells [130]. Similarly to subset #2, cases assigned to subset #1 have worse prog‐
nosis when compared to unclustered cases using the same IGHV genes [82, 85, 130].
The­aforementioned­subset­#8­(IGHV4‐39/IGKV1(D)‐39)­is­associated­with­the­highest­risk­of­
Richter’s transformation among all CLL [131]. In addition to broad polyreactivity and higher 
capacity for BCR signalling compared to subsets #1 and #2, the observed association with 
trisomy 12q and enrichment for NOTCH1 mutations likely contribute to the aggressiveness 
of subset #8 clones [124, 128].
In­contrast­to­clinically­aggressive­subsets­#1,­#2­and­#8,­subset­#4­(IGHV4‐34/IGKV2‐30),­the­
largest within M‐CLL subtype, is associated with younger age at diagnosis and remarkably 
indolent clinical course in comparison to non‐subset #4 IGHV4‐34 cases, as well as to all other 
M‐CLL cases [42, 82]. Subset #4 is characterized by CD38 negativity, the lack of recurrent 
gene mutations and the presence of favourable deletion 13q14 as the only recurrent chromo‐
somal abnormality [127, 128].­Gene­expression­profiling­and­in vitro antigenic stimulation of 
subset #4 leukemic cells revealed diminished response to BCR‐mediated signalling and the 
resemblance with anergic B cells, which probably underlie the indolent phenotype of subset 
#4 patients [132, 133].
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Given that mathematical probability of two independent B cells creating identical IG rear‐
rangements is virtually negligible, the existence of stereotyped BCRs is considered to be 
the strongest evidence for recognition of common antigens leading to selection of the CLL 
clones. This implies that BCR reactivity and intensity of response to antigenic stimulation, as 
well as the frequency of exposure to antigens, could determine the behaviour of CLL clones 
and, hence, the course of the disease. Similar clinical characteristics of cases belonging to the 
same stereotyped subset corroborate this notion. Therefore, BCR stereotypy could potentially 
become a reliable prognostic marker for at least a proportion of patients. However, most 
of­ the­clinical­variability­ in­CLL­ is­ confined­ to­cases­with­heterogeneous­BCRs,­ for­whom­
the­prognosis­definition­remains­dependent­on­IGHV­mutational­status­and­other­molecular­
markers.
4. Concluding remarks
Although the cellular origin of CLL is still a controversial issue, immunogenetic studies of 
BCR gene repertoire have provided unequivocal evidence that CLL precursor, in both M‐CLL 
and­U‐CLL­subtype,­is­an­antigen‐experienced­B­lymphocyte­[134]. Studies of antigen reac‐
tivity­have­revealed­that­U‐CLL­cells­generally­express­low‐affinity­polyreactive­BCRs­that­
recognize microbial antigens and autoantigens present on the surface of apoptotic cells (sin‐
gle‐ and double‐stranded DNA, cytoskeletal proteins, oxidized LDL and lipopolysaccharides) 
[135–139]. B cell receptors of M‐CLL cells, on the other hand, exhibit more restricted antigen 
specificities­and­are­mainly­oligo­and­monoreactive.­Auto‐reactivity­has­been­demonstrated­
for­several­stereotyped­subsets.­For­example,­it­has­been­observed­that­subset­#6­(IGHV1‐69/
IGHD3‐16/IGHJ3)­antibodies­bind­non‐muscle­myosin­heavy­chain­IIA,­exposed­on­apoptotic­
cells,­while­subset­#1(IGHV1/5/7/IGKV1(D)‐39)­recognizes­oxidized­LDL,­as­well­as­vimentin­
and calreticulin on stromal cells [137, 140, 141]. Furthermore, analysis of IGHV‐IGHD‐IGHJ 
sequence­of­subset­#4­(IGHV4‐34/IGKV2‐30)­has­indicated­similarities­with­anti‐DNA­anti‐
bodies, as well as the binding of N‐acetyllactosamine, which is a common epitope present 
on various autoantigens (I/i blood group antigen, B cell isoform of CD45) and microorgan‐
isms [142]. The recognition of bacterial and viral antigens by CLL BCRs is further supported 
by­the­association­of­persistent­infections­with­Epstein‐Barr­virus­and­cytomegalovirus­with­
subset­#4,­and­hepatitis­C­virus­with­subset­#13­(IGHV4‐59/IGKV3‐20),­the­latter­exhibiting­
rheumatoid factor activity [143, 144].­ The­ unmutated­ IGHV1‐69‐utilizing­BCRs­ have­ been­
shown to react with hepatitis C, HIV‐1 and intestinal commensal bacteria antigens [145]. In 
addition, reactivity against the capsular polysaccharides of Streptococcus pneumoniae has been 
detected, which is in agreement with the observed association of respiratory tract infections 
with elevated risk of CLL [137, 146]. Fungal antigens have also been implicated in CLL, after 
the­notion­that­mutated­IGHV3‐7/IGKV2‐24­BCRs­recognize­β‐(1,6)‐glucan,­antigenic­deter‐
minant­of­yeast­and­filamentous­fungi­[147].
Whatever the antigens might be, they clearly play a key role in the natural history of CLL. 
However, the major unanswered questions concern the moment in the disease development 
at which BCR‐antigen interaction occurs, and to what extent the nature of this  interaction 
Lymphocyte Updates - Cancer, Autoimmunity and Infection64
influences­ the­disease­progression.­Stimulation­by­auto‐­and/or­exo‐antigen­may­be­ lim‐
ited to phases prior to or during malignant transformation, leading to the selection and 
clonal expansion of precursor cell with the distinctive BCR, during which it acquires the 
oncogenic hit and becomes CLL cell [148]. Yet, it is still unclear whether antigenic stimula‐
tion continues after transformation. Several studies have investigated if CLL cells accumu‐
late somatic hypermutations post‐transformation, and have detected extensive intraclonal 
diversification­in­cases­assigned­to­stereotyped­subset­#4­(but­not­in­subsets­#2,­#8­and­#16­
and heterogeneous BCRs), implying an on‐going antigenic triggering in this subset [149, 
150].­ In­addition,­gene­expression­profiling­of­CLL­cells­ from­lymph­nodes­has­revealed­
up‐regulation of BCR target genes, thus indicating continual antigenic stimulation [122]. 
The fundamental role of BCRs in CLL is underscored by the success of newly developed 
therapeutic­strategies­targeting­BCR­signalling­pathways­(BTK,­PI3K­and­SYK­inhibitors)­
[151–154].
The­configuration­of­BCR­expressed­on­the­surface­of­ the­CLL­clone­represents­ its­specific­
molecular signature which does not change during the disease course. Hence, it is reasonable 
to believe that, in addition to IGHV mutational status, the informations about the clonotypic 
BCR will in future become important for individual patient prognostication and, ultimately, 
will­contribute­to­tailoring­of­patient‐specific­treatment­modalities.
Acknowledgements
This­work­was­supported­by­Ministry­of­Education,­Science­and­Technological­Development,­
Republic of Serbia (Grant No. III41004).
Author details
Teodora­Karan‐Djurasevic*­and­Sonja­Pavlovic
*Address all correspondence to: dora_karan@yahoo.com
Institute­of­Molecular­Genetics­and­Genetic­Engineering,­University­of­Belgrade,­Belgrade,­
Serbia
References
[1] Hallek­M.­Chronic­lymphocytic­leukemia:­2015­Update­on­diagnosis,­risk­stratification,­
and treatment. American Journal of Hematology. 2015;90(5):446‐460
[2] Dores­ GM,­Anderson­WF,­ Curtis­ RE,­ Landgren­O,­ Ostroumova­ E,­ Bluhm­ EC,­ et­ al.­
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the 
descriptive epidemiology. British Journal of Haematology. 2007;139(5):809‐819
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
65
[3] Goldin­LR,­Bjorkholm­M,­Kristinsson­SY,­Turesson­I,­Landgren­O.­Elevated­risk­of­chronic­
lymphocytic leukemia and other indolent non‐Hodgkin’s lymphomas among relatives 
of patients with chronic lymphocytic leukemia. Haematologica. 2009;94(5):647‐653
[4] Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, et al. Meta‐analysis of genome‐
wide association studies discovers multiple loci for chronic lymphocytic leukemia. 
Nature­Communications.­2016;7:10933
[5] Law­PJ,­Berndt­SI,­Speedy­HE,­Camp­NJ,­Sava­GP,­Skibola­CF,­et­al.­Genome‐wide­asso‐
ciation analysis implicates dysregulation of immunity genes in chronic lymphocytic leu‐
kaemia. Nature Communications. 2017;8:14175
[6]­ Sutton­LA,­Rosenquist­R.­The­complex­interplay­between­cell‐intrinsic­and­cell‐extrin‐
sic factors driving the evolution of chronic lymphocytic leukemia. Seminars in Cancer 
Biology. 2015;34:22‐35
[7] Dohner­H,­Stilgenbauer­S,­Benner­A,­Leupolt­E,­Krober­A,­Bullinger­L,­et­al.­Genomic­
aberrations­and­survival­in­chronic­lymphocytic­leukemia.­The­New­England­Journal­of­
Medicine. 2000;343(26):1910‐1916
[8] Austen­B,­Skowronska­A,­Baker­C,­Powell­JE,­Gardiner­A,­Oscier­D,­et­al.­Mutation­status­
of the residual ATM allele is an important determinant of the cellular response to chemo‐
therapy and survival in patients with chronic lymphocytic leukemia containing an 11q 
deletion. Journal of Clinical Oncology. 2007;25(34):5448‐5457
[9] Calin­GA,­Dumitru­CD,­Shimizu­M,­Bichi­R,­Zupo­S,­Noch­E,­et­al.­Frequent­deletions­
and­down‐regulation­of­micro‐­RNA­genes­miR15­and­miR16­at­13q14­in­chronic­lym‐
phocytic­ leukemia.­ Proceedings­ of­ the­ National­Academy­ of­ Sciences­ of­ the­ United­
States of America. 2002;99(24):15524‐15529
[10] Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, et al. Detailed analysis of 
p53­ pathway­ defects­ in­ fludarabine‐refractory­ chronic­ lymphocytic­ leukemia­ (CLL):­
Dissecting the contribution of 17p deletion, TP53 mutation, p53‐p21 dysfunction, and 
miR34a in a prospective clinical trial. Blood. 2009;114(13):2589‐2597
[11] Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al. Integrated mutational 
and­cytogenetic­analysis­ identifies­new­prognostic­subgroups­ in­chronic­ lymphocytic­
leukemia. Blood. 2013;121(8):1403‐1412
[12] Packham­G,­Stevenson­FK.­Bodyguards­and­assassins:­Bcl‐2­family­proteins­and­apopto‐
sis control in chronic lymphocytic leukaemia. Immunology. 2005;114(4):441‐449
[13] Karan‐Djurasevic­ T,­ Palibrk­ V,­ Zukic­ B,­ Spasovski­ V,­ Glumac­ I,­ Colovic­ M,­ et­ al.­
Expression­of­Bcl2L12­in­chronic­lymphocytic­leukemia­patients:­Association­with­clini‐
cal and molecular prognostic markers. Medical Oncology. 2013;30(1):405
[14] Vucicevic­K,­Jakovljevic­V,­Colovic­N,­Tosic­N,­Kostic­T,­Glumac­I,­et­al.­Association­of­
bax expression and BCL2/BAX ratio with clinical and molecular prognostic markers in 
chronic­lymphocytic­leukemia.­The­Journal­of­Biochemistry.­2016;35(2):150‐157
Lymphocyte Updates - Cancer, Autoimmunity and Infection66
[15] Niemann­CU,­Wiestner­A.­B‐cell­receptor­signaling­as­a­driver­of­lymphoma­develop‐
ment and evolution. Seminars in Cancer Biology. 2013;23(6):410‐421
[16]­ Stevenson­ FK,­ Forconi­ F,­ Packham­G.­ The­meaning­ and­ relevance­ of­ B‐cell­ receptor­
structure and function in chronic lymphocytic leukemia. Seminars in Hematology. 
2014;51(3):158‐167
[17] Hallek M, Cheson BD, Catovsky D, Caligaris‐Cappio F, Dighiero G, Dohner H, et al. 
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report 
from the International Workshop on Chronic Lymphocytic Leukemia updating the 
National­Cancer­Institute‐Working­Group­1996­guidelines.­Blood.­2008;111(12):5446‐5456
[18] Xu­JL,­Davis­MM.­Diversity­in­the­CDR3­region­of­V(H)­is­sufficient­for­most­antibody­
specificities.­Immunity.­2000;13(1):37‐45
[19] Lefranc­MP,­Pommie­C,­Ruiz­M,­Giudicelli­V,­Foulquier­E,­Truong­L,­et­al.­IMGT­unique­
numbering for immunoglobulin and T cell receptor variable domains and Ig superfam‐
ily V‐like domains. Developmental & Comparative Immunology. 2003;27(1):55‐77
[20] Lefranc­M‐P,­Lefranc­G.­The­immunoglobulin­FactsBook.­London,­UK:­Academic­Press;­
2001
[21] Lefranc MP. Nomenclature of the human immunoglobulin heavy (IGH) genes. 
Experimental­and­Clinical­Immunogenetics.­2001;18(2):100‐116
[22] Brady BL, Steinel NC, Bassing CH. Antigen receptor allelic exclusion: An update and 
reappraisal. Journal of Immunology. 2010;185(7):3801‐3808
[23] Glanville­J,­Kuo­TC,­von­Budingen­HC,­Guey­L,­Berka­J,­Sundar­PD,­et­al.­Naive­anti‐
body gene‐segment frequencies are heritable and unaltered by chronic lymphocyte abla‐
tion.­Proceedings­of­the­National­Academy­of­Sciences­of­the­United­States­of­America.­
2011;108(50):20066‐20071
[24] Schatz­DG,­ Spanopoulou­ E.­ Biochemistry­ of­V(D)J­ recombination.­ Current­ Topics­ in­
Microbiology and Immunology. 2005;290:49‐85
[25] Luning­Prak­ET,­Monestier­M,­Eisenberg­RA.­B­cell­ receptor­editing­ in­ tolerance­and­
autoimmunity. Annals of the New York Academy of Sciences. 2011;1217:96‐121
[26]­ De­ Silva­ NS,­ Klein­ U.­ Dynamics­ of­ B­ cells­ in­ germinal­ centres.­ Nature­ Reviews­
Immunology. 2015;15(3):137‐148
[27] Peled­JU,­Kuang­FL,­Iglesias‐Ussel­MD,­Roa­S,­Kalis­SL,­Goodman­MF,­et­al.­The­bio‐
chemistry of somatic hypermutation. Annual Review of Immunology. 2008;26:481‐511
[28] Stavnezer­J,­Guikema­JE,­Schrader­CE.­Mechanism­and­regulation­of­class­switch­recom‐
bination. Annual Review of Immunology. 2008;26:261‐292
[29] Damle­RN,­Wasil­T,­Fais­F,­Ghiotto­F,­Valetto­A,­Allen­SL,­et­al.­Ig­V­gene­mutation­status­
and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. 
Blood. 1999;94(6):1840‐1847
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
67
[30] Hamblin­TJ,­Davis­Z,­Gardiner­A,­Oscier­DG,­Stevenson­FK.­Unmutated­Ig­V(H)­genes­
are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 
1999;94(6):1848‐1854
[31] Maloum­K,­Davi­F,­Merle‐Beral­H,­Pritsch­O,­Magnac­C,­Vuillier­F,­et­al.­Expression­of­
unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic  leukemia. 
Blood. 2000;96(1):377‐379
[32] Thompson­PA,­Tam­CS,­O’Brien­SM,­Wierda­WG,­Stingo­F,­Plunkett­W,­et­al.­Fludarabine,­
cyclophosphamide, and rituximab treatment achieves long‐term disease‐free survival in 
IGHV‐mutated­chronic­lymphocytic­leukemia.­Blood.­2016;127(3):303‐309
[33] Fais­F,­Ghiotto­F,­Hashimoto­S,­Sellars­B,­Valetto­A,­Allen­SL,­et­al.­Chronic­lymphocytic­
leukemia B cells express restricted sets of mutated and unmutated antigen receptors. 
The Journal of Clinical Investigation. 1998;102(8):1515‐1525
[34] Ghia­P,­Stamatopoulos­K,­Belessi­C,­Moreno­C,­Stilgenbauer­S,­Stevenson­F,­et­al.­ERIC­
recommendations on IGHV gene mutational status analysis in chronic lymphocytic 
 leukemia. Leukemia. 2007;21(1):1‐3
[35] Giudicelli­V,­Brochet­X,­Lefranc­MP.­IMGT/V‐QUEST:­IMGT­standardized­analysis­of­
the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring 
Harbor Protocols. 2011;2011(6):695‐715
[36]­ Krober­A,­Seiler­T,­Benner­A,­Bullinger­L,­Bruckle­E,­Lichter­P,­et­al.­V(H)­mutation­sta‐
tus, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic 
leukemia. Blood. 2002;100(4):1410‐1416
[37] Lin­K,­Sherrington­PD,­Dennis­M,­Matrai­Z,­Cawley­JC,­Pettitt­AR.­Relationship­between­
p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leuke‐
mia. Blood. 2002;100(4):1404‐1409
[38] Tobin­G,­Thunberg­U,­Laurell­A,­Karlsson­K,­Aleskog­A,­Willander­K,­et­al.­Patients­with­
chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or 
C form a subgroup with a poor outcome. Haematologica. 2005;90(4):465‐469
[39] Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin vari‐
able region heavy chain mutations are allowable in unmutated chronic lymphocytic 
leukaemia—Long‐term­follow­up­of­patients­with­different­percentages­of­mutations.­
British Journal of Haematology. 2008;140(3):320‐323
[40] Davis ZA, Orchard JA, Corcoran MM, Oscier DG. Divergence from the germ‐line 
sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather 
than polymorphisms. Blood. 2003;102(8):3075
[41] Rassenti­LZ,­Kipps­TJ.­Lack­of­allelic­exclusion­in­B­cell­chronic­lymphocytic­leukemia.­
The­Journal­of­Experimental­Medicine.­1997;185(8):1435‐1445
[42] Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. 
Stereotyped­ patterns­ of­ somatic­ hypermutation­ in­ subsets­ of­ patients­ with­ chronic­
Lymphocyte Updates - Cancer, Autoimmunity and Infection68
 lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. 
Blood. 2008;111(3):1524‐1533
[43] Plevova­ K,­ Francova­ HS,­ Burckova­ K,­ Brychtova­ Y,­ Doubek­ M,­ Pavlova­ S,­ et­ al.­
Multiple productive immunoglobulin heavy chain gene rearrangements in chronic 
lymphocytic leukemia are mostly derived from independent clones. Haematologica. 
2014;99(2):329‐338
[44] Langerak­ AW,­ Davi­ F,­ Ghia­ P,­ Hadzidimitriou­ A,­ Murray­ F,­ Potter­ KN,­ et­ al.­
Immunoglobulin sequence analysis and prognostication in CLL: Guidelines from 
the­ ERIC­ review­ board­ for­ reliable­ interpretation­ of­ problematic­ cases.­ Leukemia.­
2011;25(6):979‐984
[45] Grever­MR,­Lucas­DM,­Dewald­GW,­Neuberg­DS,­Reed­JC,­Kitada­S,­et­al.­Comprehensive­
assessment of genetic and molecular features predicting outcome in patients with 
chronic­ lymphocytic­ leukemia:­Results­ from­the­US­ Intergroup­Phase­ III­Trial­E2997.­
Journal of Clinical Oncology. 2007;25(7):799‐804
[46]­ Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH 
testing be performed in all CLL patients at diagnosis? A systematic review and meta‐ 
analysis.­Blood.­2016;127(14):1752‐1760
[47] Oscier­DG,­Gardiner­AC,­Mould­SJ,­Glide­S,­Davis­ZA,­Ibbotson­RE,­et­al.­Multivariate­
analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational sta‐
tus, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 
2002;100(4):1177‐1184
[48] Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leu‐
kemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical 
course. Leukemia. 2002;16(6):993‐1007
[49] Haferlach­ C,­ Dicker­ F,­ Schnittger­ S,­ Kern­ W,­ Haferlach­ T.­ Comprehensive­ genetic­
characterization­ of­ CLL:­ A­ study­ on­ 506­ cases­ analysed­ with­ chromosome­ band‐
ing analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 
2007;21(12):2442‐2451
[50] Stilgenbauer­S,­Sander­S,­Bullinger­L,­Benner­A,­Leupolt­E,­Winkler­D,­et­al.­Clonal­evo‐
lution in chronic lymphocytic leukemia: Acquisition of high‐risk genomic aberrations 
associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 
2007;92(9):1242‐1245
[51] Ghia­P,­Guida­G,­Stella­S,­Gottardi­D,­Geuna­M,­Strola­G,­et­al.­The­pattern­of­CD38­
expression­defines­a­distinct­subset­of­chronic­lymphocytic­leukemia­(CLL)­patients­at­
risk of disease progression. Blood. 2003;101(4):1262‐1269
[52] Hamblin­TJ,­Orchard­JA,­Ibbotson­RE,­Davis­Z,­Thomas­PW,­Stevenson­FK,­et­al.­CD38­
expression and immunoglobulin variable region mutations are independent prognostic 
variables in chronic lymphocytic leukemia, but CD38 expression may vary during the 
course of the disease. Blood. 2002;99(3):1023‐1029
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
69
[53] Dürig­ J,­ Naschar­M,­ Schmücker­ U,­ Renzing‐Köhler­ K,­Hölter­ T,­ Hüttmann­A,­ et­ al.­
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. 
Leukemia. 2002;16(1):30‐35
[54] Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, et al. Analysis 
of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to 
clinical outcome for B‐chronic lymphocytic leukaemia. British Journal of Haematology. 
2001;115(4):854‐861
[55] Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP‐70 
expression as a surrogate for immunoglobulin‐variable‐region mutations in chronic 
lymphocytic­leukemia.­The­New­England­Journal­of­Medicine.­2003;348(18):1764‐1775
[56]­ Rassenti­LZ,­Jain­S,­Keating­MJ,­Wierda­WG,­Grever­MR,­Byrd­JC,­et­al.­Relative­value­of­
ZAP‐70, CD38, and immunoglobulin mutation status in predicting aggressive disease in 
chronic lymphocytic leukemia. Blood. 2008;112(5):1923‐1930
[57] Rassenti­LZ,­Huynh­L,­Toy­TL,­Chen­L,­Keating­MJ,­Gribben­JG,­et­al.­ZAP‐70­compared­with­
immunoglobulin heavy‐chain gene mutation status as a predictor of disease progression in 
chronic­lymphocytic­leukemia.­The­New­England­Journal­of­Medicine.­2004;351(9):893‐901
[58] Orchard­JA,­Ibbotson­RE,­Davis­Z,­Wiestner­A,­Rosenwald­A,­Thomas­PW,­et­al.­ZAP‐70­
expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363(9403):105‐111
[59] Stamatopoulos­B,­Meuleman­N,­Haibe‐Kains­B,­Duvillier­H,­Massy­M,­Martiat­P,­et­al.­
Quantification­of­ZAP70­mRNA­in­B­cells­by­real‐time­PCR­is­a­powerful­prognostic­fac‐
tor in chronic lymphocytic leukemia. Clinical Chemistry. 2007;53(10):1757‐1766
[60]­ Rosenwald­A,­Alizadeh­AA,­Widhopf­G,­Simon­R,­Davis­RE,­Yu­X,­et­al.­Relation­of­gene­
expression phenotype to immunoglobulin mutation genotype in B cell chronic lympho‐
cytic­leukemia.­The­Journal­of­Experimental­Medicine.­2001;194(11):1639‐1647
[61]­ Catherwood­MA,­Matthews­C,­Niblock­R,­Dobbin­E,­Morris­TC,­Alexander­HD.­ZAP‐70­
mRNA­ quantification­ in­ B‐cell­ chronic­ lymphocytic­ leukaemia.­ European­ Journal­ of­
Haematology.­2006;76(4):294‐298
[62]­ Krober­A,­Bloehdorn­J,­Hafner­S,­Buhler­A,­Seiler­T,­Kienle­D,­et­al.­Additional­genetic­
high‐risk features such as 11q deletion, 17p deletion, and V3‐21 usage characterize dis‐
cordance of ZAP‐70 and VH mutation status in chronic lymphocytic leukemia. Journal 
of­Clinical­Oncology.­2006;24(6):969‐975
[63]­ Wiestner­A,­Rosenwald­A,­Barry­TS,­Wright­G,­Davis­RE,­Henrickson­SE,­et­al.­ZAP‐70­
expression­identifies­a­chronic­lymphocytic­leukemia­subtype­with­unmutated­immu‐
noglobulin­genes,­inferior­clinical­outcome,­and­distinct­gene­expression­profile.­Blood.­
2003;101(12):4944‐4951
[64]­ Heintel­D,­Kienle­D,­Shehata­M,­Krober­A,­Kroemer­E,­Schwarzinger­I,­et­al.­High­expres‐
sion of lipoprotein lipase in poor risk B‐cell chronic lymphocytic leukemia. Leukemia. 
2005;19(7):1216‐1223
Lymphocyte Updates - Cancer, Autoimmunity and Infection70
[65]­ Nikitin­ EA,­Malakho­ SG,­ Biderman­ BV,­ Baranova­AV,­ Lorie­ YY,­ Shevelev­AY,­ et­ al.­
Expression­ level­of­ lipoprotein­ lipase­and­dystrophin­genes­predict­ survival­ in­B‐cell­
chronic lymphocytic leukemia. Leukemia & Lymphoma. 2007;48(5):912‐922
[66]­ Van­ Bockstaele­ F,­ Pede­ V,­ Janssens­ A,­ Callewaert­ F,­ Offner­ F,­ Verhasselt­ B,­ et­ al.­
Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell 
chronic lymphocytic leukemia. Clinical Chemistry. 2007;53(2):204‐212
[67]­ Mansouri­M,­Sevov­M,­Fahlgren­E,­Tobin­G,­Jondal­M,­Osorio­L,­et­al.­Lipoprotein­lipase­
is­differentially­expressed­ in­prognostic­ subsets­of­ chronic­ lymphocytic­ leukemia­but­
displays invariably low catalytical activity. Leukemia Research. 2010;34(3):301‐306
[68]­ Nuckel­ H,­ Huttmann­ A,­ Klein‐Hitpass­ L,­ Schroers­ R,­ Fuhrer­ A,­ Sellmann­ L,­ et­ al.­
Lipoprotein lipase expression is a novel prognostic factor in B‐cell chronic lymphocytic 
leukemia.­Leuk­Lymphoma.­2006;47(6):1053‐1061
[69]­ Kaderi­MA,­Kanduri­M,­Buhl­AM,­Sevov­M,­Cahill­N,­Gunnarsson­R,­et­al.­LPL­is­the­
strongest prognostic factor in a comparative analysis of RNA‐based markers in early 
chronic lymphocytic leukemia. Haematologica. 2011;96(8):1153‐1160
[70] Antic­D,­Mihaljevic­B,­Cokic­V,­Fekete­MD,­Djurasevic­TK,­Pavlovic­S,­et­al.­Patients­with­
early­stage­chronic­ lymphocytic­ leukemia:­New­risk­stratification­based­on­molecular­
profiling.­Leuk­Lymphoma.­2011;52(7):1394‐1397
[71] van’t Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland 
WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic 
leukemia.­Haematologica.­2006;91(1):56‐63
[72] International CLL‐IPI working group. An international prognostic index for patients 
with chronic lymphocytic leukaemia (CLL‐IPI): a meta‐analysis of individual patient 
data. The Lancet Oncology.­2016;17(6):779‐790
[73] Delgado­J,­Doubek­M,­Baumann­T,­Kotaskova­J,­Molica­S,­Mozas­P,­et­al.­Chronic­lym‐
phocytic leukemia: A prognostic model comprising only two biomarkers (IGHV muta‐
tional­ status­ and­ FISH­ cytogenetics)­ separates­ patients­ with­ different­ outcome­ and­
simplifies­the­CLL‐IPI.­American­Journal­of­Hematology.­2017;92(4):375‐380.
[74] Pflug­N,­Bahlo­J,­Shanafelt­TD,­Eichhorst­BF,­Bergmann­MA,­Elter­T,­et­al.­Development­
of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. 
Blood. 2014;124(1):49‐62
[75] Visentin­A,­Frezzato­F,­Imbergamo­S,­Trimarco­V,­Martini­V,­Severin­F,­et­al.­Evaluation­
of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic 
Leukemia. Blood. 2016;128(22):5563‐5563
[76]­ Brezinschek­ HP,­ Foster­ SJ,­ Brezinschek­ RI,­ Dorner­ T,­ Domiati‐Saad­ R,­ Lipsky­ PE.­
Analysis­of­the­human­VH­gene­repertoire.­Differential­effects­of­selection­and­somatic­
hypermutation on human peripheral CD5(+)/IgM+ and CD5(‐)/IgM+ B cells. The Journal 
of Clinical Investigation. 1997;99(10):2488‐2501
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
71
[77] Schroeder Jr. HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: 
Analysis of the antibody repertoire. Immunology Today. 1994;15(6):288‐294
[78] Duke­VM,­Gandini­D,­Sherrington­PD,­Lin­K,­Heelan­B,­Amlot­P,­et­al.­V(H)­gene­usage­
differs­in­germline­and­mutated­B‐cell­chronic­lymphocytic­leukemia.­Haematologica.­
2003;88(11):1259‐1271
[79] Ghia­ P,­ Stamatopoulos­K,­ Belessi­ C,­Moreno­C,­ Stella­ S,­Guida­G,­ et­ al.­Geographic­
patterns­ and­ pathogenetic­ implications­ of­ IGHV­ gene­ usage­ in­ chronic­ lymphocytic­
 leukemia: The lesson of the IGHV3‐21 gene. Blood. 2005;105(4):1678‐1685
[80] Mauerer­K,­Zahrieh­D,­Gorgun­G,­Li­A,­Zhou­J,­Ansen­S,­et­al.­Immunoglobulin­gene­
segment usage, location and immunogenicity in mutated and unmutated chronic lym‐
phocytic leukaemia. British journal of Haematology. 2005;129(4):499‐510
[81] Messmer­BT,­Albesiano­E,­Messmer­D,­Chiorazzi­N.­ The­ pattern­ and­distribution­ of­
immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are con‐
sistent with the canonical somatic hypermutation process. Blood. 2004;103(9):3490‐3495
[82] Stamatopoulos­K,­ Belessi­ C,­Moreno­C,­ Boudjograh­M,­Guida­G,­ Smilevska­ T,­ et­ al.­
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: 
Pathogenetic implications and clinical correlations. Blood. 2007;109(1):259‐270
[83] Widhopf­2nd­GF,­Kipps­TJ.­Normal­B­cells­express­51p1‐encoded­Ig­heavy­chains­that­
are distinct from those expressed by chronic lymphocytic leukemia B cells. Journal of 
Immunology. 2001;166(1):95‐102
[84] Potter­KN,­Orchard­J,­Critchley­E,­Mockridge­CI,­Jose­A,­Stevenson­FK.­Features­of­the­
overexpressed­V1‐69­genes­in­the­unmutated­subset­of­chronic­lymphocytic­leukemia­
are distinct from those in the healthy elderly repertoire. Blood. 2003;101(8):3082‐3084
[85] Bomben­ R,­ Dal­ Bo­M,­ Capello­ D,­ Forconi­ F,­Maffei­ R,­ Laurenti­ L,­ et­ al.­Molecular­
and clinical features of chronic lymphocytic leukaemia with stereotyped B cell recep‐
tors: Results from an Italian multicentre study. British Journal of Haematology. 
2009;144(4):492‐506
[86]­ Bilous N, Bomben R, Dal Bo M, Capello D, Forconi F, Laurenti L, et al. Molecular and 
clinical features of chronic lymphocytic leukemia with stereotyped B‐cell receptors in a 
Ukrainian­cohort.­Leuk­Lymphoma.­2010;51(5):822‐838
[87] Karan‐Djurasevic­ T,­ Palibrk­ V,­ Kostic­ T,­ Spasovski­ V,­ Nikcevic­ G,­ Srzentic­ S,­ et­ al.­
Mutational status and gene repertoire of IGHV‐IGHD‐IGHJ rearrangements in Serbian 
patients with chronic lymphocytic leukemia. Clinical Lymphoma, Myeloma & Leukemia. 
2012;12(4):252‐260
[88] Bianchi S, Moreno P, Landoni AI, Naya H, Oppezzo P, Dighiero G, et al. Immunoglobulin 
heavy­ chain­V‐D‐J­gene­ rearrangement­ and­mutational­ status­ in­Uruguayan­patients­
with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(11):2070‐2078
Lymphocyte Updates - Cancer, Autoimmunity and Infection72
[89] Gonzalez‐Gascon­YMI,­Hernandez­JA,­Martin­A,­Alcoceba­M,­Sarasquete­ME,­Rodriguez‐
Vicente A, et al. Mutation status and immunoglobulin gene rearrangements in patients 
from northwest and central region of Spain with chronic lymphocytic leukemia. BioMed 
Research International. 2014;2014:257517
[90] Tobin­G,­Thunberg­U,­Johnson­A,­Thorn­I,­Soderberg­O,­Hultdin­M,­et­al.­Somatically­
mutated Ig V(H)3‐21 genes characterize a new subset of chronic lymphocytic leukemia. 
Blood. 2002;99(6):2262‐2264
[91] Tobin­G,­Thunberg­U,­Johnson­A,­Eriksson­I,­Soderberg­O,­Karlsson­K,­et­al.­Chronic­
lymphocytic leukemias utilizing the VH3‐21 gene display highly restricted Vlambda2‐14 
gene use and homologous CDR3s: Implicating recognition of a common antigen  epitope. 
Blood. 2003;101(12):4952‐4957
[92] Matthews­C,­Catherwood­MA,­Morris­TC,­Alexander­HD.­V(H)3‐48­and­V(H)3‐53,­as­
well­as­V(H)3‐21,­gene­rearrangements­define­unique­subgroups­in­CLL­and­are­associ‐
ated with biased lambda light chain restriction, homologous LCDR3 sequences and poor 
prognosis. Leukemia Research. 2007;31(2):231‐234
[93] Bomben­ R,­ Dal­ Bo­ M,­ Capello­ D,­ Benedetti­ D,­ Marconi­ D,­ Zucchetto­ A,­ et­ al.­
Comprehensive characterization of IGHV3‐21‐expressing B‐cell chronic lymphocytic 
leukemia: An Italian multicenter study. Blood. 2007;109(7):2989‐2998
[94] Hojjat‐Farsangi­M,­ Jeddi‐Tehrani­M,­Razavi­SM,­Sharifian­RA,­Mellstedt­H,­Shokri­F,­
et al. Immunoglobulin heavy chain variable region gene usage and mutational status 
of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer 
Science. 2009;100(12):2346‐2353
[95] Chen L, Zhang Y, Zheng W, Wu Y, Qiao C, Fan L, et al. Distinctive IgVH gene segments 
usage and mutation status in Chinese patients with chronic lymphocytic leukemia. 
Leukemia Research. 2008;32(10):1491‐1498
[96]­ Koiso­ H,­ Yamane­ A,­ Mitsui­ T,­ Matsushima­ T,­ Tsukamoto­ N,­ Murakami­ H,­ et­ al.­
Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lympho‐
cytic­leukemia.­Leukemia­Research.­2006;30(3):272‐276
[97] Ghiotto­F,­Fais­F,­Albesiano­E,­Sison­C,­Valetto­A,­Gaidano­G,­et­al.­Similarities­and­dif‐
ferences between the light and heavy chain Ig variable region gene repertoires in chronic 
lymphocytic­leukemia.­Molecular­Medicine.­2006;12(11‐12):300‐308
[98] Stamatopoulos­K,­ Belessi­ C,­Hadzidimitriou­A,­ Smilevska­ T,­ Kalagiakou­ E,­Hatzi­K,­
et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood. 
2005;106(10):3575‐3583
[99] Belessi­C,­Stamatopoulos­K,­Hadzidimitriou­A,­Hatzi­K,­Smilevska­T,­Stavroyianni­N,­
et­ al.­Analysis­ of­ expressed­ and­non‐expressed­ IGK­ locus­ rearrangements­ in­ chronic­
lymphocytic leukemia. Molecular Medicine. 2005;11(1‐12):52‐58
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
73
[100] Widhopf GF, 2nd, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, et al. 
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by 
chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 
2008;111(6):3137‐3144
[101] Brezinschek­HP,­Foster­ SJ,­Dorner­T,­Brezinschek­RI,­Lipsky­PE.­Pairing­of­variable­
heavy and variable kappa chains in individual naive and memory B cells. Journal of 
Immunology. 1998;160(10):4762‐4767
[102] de Wildt RM, Hoet RM, van Venrooij WJ, Tomlinson IM, Winter G. Analysis of heavy 
and light chain pairings indicates that receptor editing shapes the human antibody 
repertoire. Journal of Molecular Biology. 1999;285(3):895‐901
[103] Lin­K,­Manocha­ S,­Harris­RJ,­Matrai­Z,­ Sherrington­PD,­Pettitt­AR.­High­ frequency­
of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia 
patients using the VH3‐21 gene segment. Blood. 2003;102(3):1145‐1146
[104] Thorselius­M,­Krober­A,­Murray­F,­Thunberg­U,­Tobin­G,­Buhler­A,­et­al.­Strikingly­
homologous immunoglobulin gene rearrangements and poor outcome in VH3‐21‐
using chronic lymphocytic leukemia patients independent of geographic origin and 
mutational­status.­Blood.­2006;107(7):2889‐2894
[105] Bomben­R,­Dal‐Bo­M,­Benedetti­D,­Capello­D,­Forconi­F,­Marconi­D,­et­al.­Expression­
of­mutated­IGHV3‐23­genes­in­chronic­lymphocytic­leukemia­identifies­a­disease­subset­
with peculiar clinical and biological features. Clinical Cancer Research. 2010;16(2):620‐628
[106]­ Capello­D,­Guarini­A,­Berra­E,­Mauro­FR,­Rossi­D,­Ghia­E,­et­al.­Evidence­of­biased­
immunoglobulin variable gene usage in highly stable B‐cell chronic lymphocytic leuke‐
mia. Leukemia. 2004;18(12):1941‐1947
[107] Del­ Giudice­ I,­ Chiaretti­ S,­ Tavolaro­ S,­ De­ Propris­MS,­Maggio­ R,­Mancini­ F,­ et­ al.­
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic fea‐
tures of 9 cases. Blood. 2009;114(3):638‐646
[108] Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annual Review of 
Immunology. 2009;27:267‐285
[109] Damle­RN,­Ghiotto­F,­Valetto­A,­Albesiano­E,­Fais­F,­Yan­XJ,­et­al.­B‐cell­chronic­lym‐
phocytic leukemia cells express a surface membrane phenotype of activated, antigen‐
experienced B lymphocytes. Blood. 2002;99(11):4087‐4093
[110] Klein­ U,­ Tu­ Y,­ Stolovitzky­ GA,­ Mattioli­ M,­ Cattoretti­ G,­ Husson­ H,­ et­ al.­ Gene­
expression­profiling­of­B­cell­chronic­lymphocytic­leukemia­reveals­a­homogeneous­
­phenotype­ related­ to­memory­B­cells.­The­ Journal­of­Experimental­Medicine.­2001; 
194(11):1625‐1638
[111] Messmer­BT,­Albesiano­E,­Efremov­DG,­Ghiotto­F,­Allen­SL,­Kolitz­J,­et­al.­Multiple­dis‐
tinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic 
lymphocytic­leukemia.­The­Journal­of­Experimental­Medicine.­2004;200(4):519‐525
Lymphocyte Updates - Cancer, Autoimmunity and Infection74
[112] Ghiotto­F,­Fais­F,­Valetto­A,­Albesiano­E,­Hashimoto­S,­Dono­M,­et­al.­Remarkably­simi‐
lar antigen receptors among a subset of patients with chronic lymphocytic leukemia. 
The Journal of Clinical Investigation. 2004;113(7):1008‐1016
[113] Tobin­G,­Thunberg­U,­Karlsson­K,­Murray­F,­Laurell­A,­Willander­K,­et­al.­Subsets­with­
restricted immunoglobulin gene rearrangement features indicate a role for antigen selec‐
tion in the development of chronic lymphocytic leukemia. Blood. 2004;104(9):2879‐2885
[114] Widhopf­GF,­2nd,­Rassenti­LZ,­Toy­TL,­Gribben­ JG,­Wierda­WG,­Kipps­TJ.­Chronic­
lymphocytic leukemia B cells of more than 1% of patients express virtually identical 
immunoglobulins. Blood. 2004;104(8):2499‐2504
[115] Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. 
Stereotyped B‐cell receptors in one‐third of chronic lymphocytic leukemia: A molecular 
classification­with­implications­for­targeted­therapies.­Blood.­2012;119(19):4467‐4475
[116]­ Stamatopoulos­K,­Agathangelidis­A,­Rosenquist­R,­Ghia­P.­Antigen­receptor­stereotypy­
in chronic lymphocytic leukemia. Leukemia. 2017;31(2):282‐291
[117] Darzentas­N,­Hadzidimitriou­A,­Murray­F,­Hatzi­K,­Josefsson­P,­Laoutaris­N,­et­al.­A­
different­ontogenesis­for­chronic­lymphocytic­leukemia­cases­carrying­stereotyped­anti‐
gen receptors: Molecular and computational evidence. Leukemia. 2010;24(1):125‐132
[118] Hadzidimitriou­A,­Darzentas­N,­Murray­F,­Smilevska­T,­Arvaniti­E,­Tresoldi­C,­et­al.­
Evidence­for­the­significant­role­of­immunoglobulin­light­chains­in­antigen­recognition­
and selection in chronic lymphocytic leukemia. Blood. 2009;113(2):403‐411
[119] Caligaris‐Cappio F, Bertilaccio MT, Scielzo C. How the microenvironment wires 
the natural history of chronic lymphocytic leukemia. Seminars in Cancer Biology. 
2014;24:43‐48
[120] Chen­L,­Widhopf­G,­Huynh­L,­Rassenti­L,­Rai­KR,­Weiss­A,­et­al.­Expression­of­ZAP‐70­
is associated with increased B‐cell receptor signaling in chronic lymphocytic leukemia. 
Blood. 2002;100(13):4609‐4614
[121] Lanham­S,­Hamblin­T,­Oscier­D,­Ibbotson­R,­Stevenson­F,­Packham­G.­Differential­sig‐
naling via surface IgM is associated with VH gene mutational status and CD38 expres‐
sion in chronic lymphocytic leukemia. Blood. 2003;101(3):1087‐1093
[122] Herishanu­Y,­Perez‐Galan­P,­Liu­D,­Biancotto­A,­Pittaluga­S,­Vire­B,­et­al.­The­lymph­
node microenvironment promotes B‐cell receptor signaling, NF‐kappaB activation, and 
tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563‐574
[123] Guarini­A,­Chiaretti­S,­Tavolaro­S,­Maggio­R,­Peragine­N,­Citarella­F,­et­al.­BCR­ligation­
induced by IgM stimulation results in gene expression and functional changes only in 
IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112(3):782‐792
[124] Baliakas­P,­Hadzidimitriou­A,­ Sutton­LA,­Minga­E,­Agathangelidis­A,­Nichelatti­M,­
et­ al.­Clinical­ effect­of­ stereotyped­B‐cell­ receptor­ immunoglobulins­ in­ chronic­ lym‐
phocytic leukaemia: A retrospective multicentre study. The Lancet Haematology. 
2014;1(2):e74‐e84
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
75
[125] Maura F, Cutrona G, Fabris S, Colombo M, Tuana G, Agnelli L, et al. Relevance of 
stereotyped B‐cell receptors in the context of the molecular, cytogenetic and clinical 
features of chronic lymphocytic leukemia. PLoS One. 2011;6(8):e24313
[126]­ Gounari M, Ntoufa S, Apollonio B, Papakonstantinou N, Ponzoni M, Chu CC, et al. 
Excessive­antigen­reactivity­may­underlie­the­clinical­aggressiveness­of­chronic­ lym‐
phocytic leukemia stereotyped subset #8. Blood. 2015;125(23):3580‐3587
[127] Marincevic M, Cahill N, Gunnarsson R, Isaksson A, Mansouri M, Goransson H, et al. 
High‐density­screening­reveals­a­different­spectrum­of­genomic­aberrations­in­chronic­
lymphocytic leukemia patients with ‘stereotyped’ IGHV3‐21 and IGHV4‐34 B‐cell 
receptors. Haematologica. 2010;95(9):1519‐1525
[128] Sutton­ LA,­ Young­ E,­ Baliakas­ P,­ Hadzidimitriou­A,­Moysiadis­ T,­ Plevova­ K,­ et­ al.­
Different­spectra­of­recurrent­gene­mutations­in­subsets­of­chronic­lymphocytic­leuke‐
mia­harboring­stereotyped­B‐cell­receptors.­Haematologica.­2016;101(8):959‐967
[129] Baliakas­P,­Agathangelidis­A,­Hadzidimitriou­A,­Sutton­LA,­Minga­E,­Tsanousa­A,­et­al.­
Not all IGHV3‐21 chronic lymphocytic leukemias are equal: Prognostic considerations. 
Blood. 2015;125(5):856‐859
[130] Del­Giudice­ I,­Chiaretti­ S,­ Santangelo­ S,­ Tavolaro­ S,­ Peragine­N,­Marinelli­M,­ et­ al.­
Stereotyped subset #1 chronic lymphocytic leukemia: A direct link between B‐cell 
receptor structure, function, and patients’ prognosis. American Journal of Hematology. 
2014;89(1):74‐82
[131] Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, et al. Stereotyped B‐cell 
receptor is an independent risk factor of chronic lymphocytic leukemia transformation 
to Richter syndrome. Clinical Cancer Research. 2009;15(13):4415‐4422
[132] Marincevic­M,­Mansouri­M,­Kanduri­M,­Isaksson­A,­Goransson­H,­Smedby­KE,­et­al.­
Distinct­gene­expression­profiles­in­subsets­of­chronic­lymphocytic­leukemia­express‐
ing stereotyped IGHV4‐34 B‐cell receptors. Haematologica. 2010;95(12):2072‐2079
[133] Ntoufa­S,­Papakonstantinou­N,­Apollonio­B,­Gounari­M,­Galigalidou­C,­Fonte­E,­et­al.­
B cell anergy modulated by TLR1/2 and the miR‐17 approximately 92 cluster under‐
lies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. 
Journal­of­Immunology.­2016;196(10):4410‐4417
[134] Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary 
notes and additional considerations and possibilities. Blood. 2011;117(6):1781‐1791
[135] Herve­M,­Xu­K,­Ng­YS,­Wardemann­H,­Albesiano­E,­Messmer­BT,­et­al.­Unmutated­
and mutated chronic lymphocytic leukemias derive from self‐reactive B cell precursors 
despite­expressing­different­antibody­reactivity.­The­Journal­of­Clinical­Investigation.­
2005;115(6):1636‐1643
[136]­ Catera­R,­Silverman­GJ,­Hatzi­K,­Seiler­T,­Didier­S,­Zhang­L,­et­al.­Chronic­lymphocytic­
leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. 
Molecular Medicine. 2008;14(11‐12):665‐674
Lymphocyte Updates - Cancer, Autoimmunity and Infection76
[137] Lanemo­Myhrinder­A,­Hellqvist­E,­Sidorova­E,­Soderberg­A,­Baxendale­H,­Dahle­C,­et­
al. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria 
are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111(7):3838‐3848
[138] Zwick­C,­Fadle­N,­Regitz­E,­Kemele­M,­Stilgenbauer­S,­Buhler­A,­et­al.­Autoantigenic­
targets of B‐cell receptors derived from chronic lymphocytic leukemias bind to and 
induce proliferation of leukemic cells. Blood. 2013;121(23):4708‐4717
[139] Seiler­T,­Woelfle­M,­Yancopoulos­S,­Catera­R,­Li­W,­Hatzi­K,­ et­ al.­Characterization­
of­ structurally­ defined­ epitopes­ recognized­ by­monoclonal­ antibodies­ produced­ by­
chronic lymphocytic leukemia B cells. Blood. 2009;114(17):3615‐3624
[140] Binder­M,­Lechenne­B,­Ummanni­R,­Scharf­C,­Balabanov­S,­Trusch­M,­et­al.­Stereotypical­
chronic lymphocytic leukemia B‐cell receptors recognize survival promoting antigens 
on stromal cells. PLoS One. 2010;5(12):e15992
[141] Chu­CC,­Catera­R,­Hatzi­K,­Yan­XJ,­Zhang­L,­Wang­XB,­ et­ al.­Chronic­ lymphocytic­
leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle 
myosin heavy chain IIA. Blood. 2008;112(13):5122‐5129
[142] Potter­KN,­Hobby­P,­Klijn­S,­Stevenson­FK,­Sutton­BJ.­Evidence­for­involvement­of­a­
hydrophobic patch in framework region 1 of human V4‐34‐encoded Igs in recognition 
of the red blood cell I antigen. Journal of Immunology. 2002;169(7):3777‐3782
[143] Kostareli­E,­Hadzidimitriou­A,­Stavroyianni­N,­Darzentas­N,­Athanasiadou­A,­Gounari­
M,­et­al.­Molecular­evidence­for­EBV­and­CMV­persistence­in­a­subset­of­patients­with­
chronic lymphocytic leukemia expressing stereotyped IGHV4‐34 B‐cell receptors. 
Leukemia. 2009;23(5):919‐924
[144] Kostareli­E,­Gounari­M,­Janus­A,­Murray­F,­Brochet­X,­Giudicelli­V,­et­al.­Antigen­recep‐
tor­ stereotypy­ across­ B‐cell­ lymphoproliferations:­ The­ case­ of­ IGHV4‐59/IGKV3‐20­
receptors with rheumatoid factor activity. Leukemia. 2012;26(5):1127‐1131
[145] Hwang­KK,­Trama­AM,­Kozink­DM,­Chen­X,­Wiehe­K,­Cooper­AJ,­ et­ al.­ IGHV1‐69­
B cell chronic lymphocytic leukemia antibodies cross‐react with HIV‐1 and hepatitis 
C virus antigens as well as intestinal commensal bacteria. PLoS One. 2014;9(3):e90725
[146]­ Landgren­O,­ Rapkin­ JS,­ Caporaso­NE,­Mellemkjaer­ L,­ Gridley­G,­Goldin­ LR,­ et­ al.­
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. 
Blood. 2007;109(5):2198‐2201
[147] Hoogeboom­R,­van­Kessel­KP,­Hochstenbach­F,­Wormhoudt­TA,­Reinten­RJ,­Wagner­K,­
et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and 
responds­to­fungi.­The­Journal­of­Experimental­Medicine.­2013;210(1):59‐70
[148] Rosen­ A,­ Murray­ F,­ Evaldsson­ C,­ Rosenquist­ R.­ Antigens­ in­ chronic­ lymphocytic­
 leukemia—Implications for cell origin and leukemogenesis. Seminars in Cancer Biology. 
2010;20(6):400‐409
[149] Sutton­LA,­Kostareli­E,­Hadzidimitriou­A,­Darzentas­N,­Tsaftaris­A,­Anagnostopoulos­
A,­ et­ al.­ Extensive­ intraclonal­ diversification­ in­ a­ subgroup­ of­ chronic­ lymphocytic­
Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in ...
http://dx.doi.org/10.5772/intechopen.69110
77
 leukemia patients with stereotyped IGHV4‐34 receptors: Implications for ongoing 
interactions with antigen. Blood. 2009;114(20):4460‐4468
[150] Kostareli­E,­Sutton­LA,­Hadzidimitriou­A,­Darzentas­N,­Kouvatsi­A,­Tsaftaris­A,­et­al.­
Intraclonal­ diversification­ of­ immunoglobulin­ light­ chains­ in­ a­ subset­ of­ chronic­
lymphocytic leukemia alludes to antigen‐driven clonal evolution. Leukemia. 
2010;24(7):1317‐1324
[151] Woyach­ JA,­ Smucker­ K,­ Smith­ LL,­ Lozanski­ A,­ Zhong­ Y,­ Ruppert­ AS,­ et­ al.­
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molec‐
ular characteristics and does not indicate a suboptimal response to therapy. Blood. 
2014;123(12):1810‐1817
[152] Byrd­JC,­Furman­RR,­Coutre­SE,­Flinn­IW,­Burger­JA,­Blum­KA,­et­al.­Targeting­BTK­
with­ibrutinib­in­relapsed­chronic­lymphocytic­leukemia.­The­New­England­Journal­of­
Medicine. 2013;369(1):32‐42
[153] Furman­RR,­Sharman­JP,­Coutre­SE,­Cheson­BD,­Pagel­JM,­Hillmen­P,­et­al.­Idelalisib­
and­rituximab­in­relapsed­chronic­lymphocytic­leukemia.­The­New­England­Journal­of­
Medicine. 2014;370(11):997‐1007
[154] Herman­SE,­Barr­PM,­McAuley­EM,­Liu­D,­Wiestner­A,­Friedberg­JW.­Fostamatinib­inhib‐
its B‐cell receptor signaling, cellular activation and tumor proliferation in patients with 
relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2013;27(8):1769‐1773
Lymphocyte Updates - Cancer, Autoimmunity and Infection78
